Previous close | 0.5100 |
Open | 0.6600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 300.00 |
Expiry date | 2025-01-17 |
Day's range | 0.5100 - 0.6700 |
Contract range | N/A |
Volume | |
Open interest | N/A |
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: